FTC Secures $12 Million Penalty Over Edwards Lifesciences Deal

Key Takeaways

• Record HSR Penalty: The proposed $12 million settlement is the largest penalty ever secured for failing to make a required Hart-Scott-Rodino filing.
• Connected Payments: The FTC alleges that Edwards and Genesis kept the acquisition price below the reporting threshold while arranging a related $25 million investment that pushed the combined value above it.
• Competition Concerns: One day after acquiring JC Medical, Edwards attempted to buy JenaValve, which would have given it control of the only two companies with TAVR-AR devices in U.S. clinical trials.
• Prior Notice Required: Edwards would have to notify the FTC before acquiring interests in certain companies developing or selling TAVR-AR devices in the U.S.

Deep Dive

Edwards Lifesciences paid $115 million for JC Medical in July 2024, an amount that landed just beneath the $119.5 million threshold that would have required the transaction to be reported to federal antitrust authorities. It was close, but close does not count in a statute governed by arithmetic. The Federal Trade Commission says the math was incomplete.

Alongside the acquisition, Edwards agreed to invest another $25 million in JC Medical’s parent, Genesis MedTech Group Limited. The FTC alleges that the investment was part of the same economic arrangement and that, taken together, the payments pushed the transaction well beyond the threshold for mandatory reporting under the Hart-Scott-Rodino Act. By separating them, the agency contends, Edwards and Genesis were able to complete the acquisition without submitting a premerger filing or waiting for regulators to examine what they were buying and why it mattered.

That is now a $12 million mistake. The FTC announced Monday that it had reached a proposed settlement with Edwards, JC Medical and Genesis over the unreported acquisition, the largest penalty ever obtained for failing to make a required HSR filing. Edwards and JC Medical, a former Genesis subsidiary, would pay $10 million. Genesis would pay the remaining $2 million.

“Companies that try to sneak deals through without lawful FTC review should take notice,” FTC Chairman Andrew N. Ferguson said. “The FTC will be vigilant in enforcing the requirements of the Hart-Scott-Rodino Act and we will not hesitate to seek penalties for its violation.”

The settlement still requires approval from a federal judge. Its entry would not constitute an admission or finding of wrongdoing or liability, and the defendants deny violating the law. The numbers explain how the deal escaped review. What happened next explains why the FTC cares.

JC Medical was conducting clinical trials for a transcatheter aortic valve replacement device designed to treat aortic regurgitation, a condition in which the heart’s aortic valve does not close properly. At the time, only one other company in the United States, JenaValve Technology Inc., had a competing TAVR-AR device in clinical trials. One day after completing its acquisition of JC Medical, Edwards attempted to buy JenaValve.

Had the second transaction succeeded, Edwards would have owned the only two companies with TAVR-AR devices in U.S. clinical trials. The FTC sued to block that acquisition, alleging it would harm competition. In January 2026, after a six-day hearing, the U.S. District Court for the District of Columbia granted the agency’s request for a preliminary injunction.

The sequence gave the unreported JC Medical acquisition a different cast. According to the FTC’s complaint, Edwards was concerned that an HSR review of that deal would delay closing, particularly while it was negotiating to acquire JenaValve. The waiting period was not an incidental inconvenience. It was the part of the law that would have given federal agencies time to see the two deals together.

The Hart-Scott-Rodino Act is built around that pause. Transactions meeting its requirements must be disclosed to the FTC and Justice Department before they close, allowing the agencies to investigate whether an acquisition could diminish competition while there is still something practical to prevent. Once assets have changed hands and businesses have been absorbed, scrutiny becomes a more complicated and less useful instrument.

The complaint therefore treats the $25 million investment not as a neighboring transaction but as part of the price paid to secure JC Medical. The legal question asks whether companies may avoid review by arranging connected payments so that the acquisition itself appears to fall below the reporting line. The FTC’s answer is unambiguous.

The proposed judgment would impose restraints that reach beyond the financial penalty. Edwards would have to provide the FTC with advance written notice before acquiring any ownership interest in certain companies active in the U.S. market for TAVR-AR devices. The requirement would cover businesses that commercially sell such a device, conduct U.S. clinical trials involving one or have received an Investigational Device Exemption from the Food and Drug Administration to begin those trials.

Edwards would also have to design, maintain and operate an antitrust compliance program to ensure adherence to the final judgment and federal antitrust laws. The requirement places the transaction inside the company’s compliance machinery, where the question will no longer be merely whether a deal’s stated price clears a statutory threshold, but whether all of its connected parts tell a different story.

The GRC Report is your premier destination for the latest in governance, risk, and compliance news. As your reliable source for comprehensive coverage, we ensure you stay informed and ready to navigate the dynamic landscape of GRC. Beyond being a news source, the GRC Report represents a thriving community of professionals who, like you, are dedicated to GRC excellence. Explore our insightful articles and breaking news, and actively participate in the conversation to enhance your GRC journey.